Working… Menu
Trial record 54 of 280 for:    Panama

Cost Effectiveness Of Sunitinib In Central America And Caribbean

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01033981
Recruitment Status : Terminated (See termination reason in detailed description.)
First Posted : December 17, 2009
Last Update Posted : April 19, 2012
Information provided by (Responsible Party):

Brief Summary:
Primary Hypothesis: The therapy with Sunitinib represents better cost-effectiveness than IFN-α in first-line treatment for metastatic Renal Cell Carcinoma (mRCC) in Central America and Caribbean countries

Condition or disease Intervention/treatment
Metastatic Renal Cell Carcinoma Drug: Sunitinib

Detailed Description:
This study was terminated on 03Feb2011 due to the fact that the anticipated number of patients expected was not reached. The date of cessation of the drug was January 27, 2011. There was no intervention in the treatment or administration of the drug; the study only observed the treatment and collected data. As the study was dependent on the arrival of new patients with metastatic renal cancer, which was of a very low incidence, the study was terminated. Efficacy, adverse events or other safety issues were not factors in terminating the study. Lack of patients was the only reason.

Layout table for study information
Study Type : Observational
Actual Enrollment : 4 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Cost Effectiveness Of Sunitinib Vs IFN-Alfa Or Bevacizumab + IFN-Alfa As First-Line Treatment In MRCC In Central America And The Caribbean
Study Start Date : May 2010
Actual Primary Completion Date : February 2011
Actual Study Completion Date : February 2011

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Central America and Caribbean
Dominican Republic, Guatemala, Panama, Costa Rica, Honduras, Trinidad & Tobago
Drug: Sunitinib
Treatment for mRCC as indication approved and physician criterium

Primary Outcome Measures :
  1. Rate of patients that present metastasis when consulting for first time [ Time Frame: 9 months ]
  2. Rate of use of Sutent, IFN-α and Bevacizumab + IFN-α as first-line treatment [ Time Frame: 9 months ]
  3. Hospitalization average with Sutent, with IFN-α, and with Bevacizumab + IFN-α [ Time Frame: 9 months ]
  4. Rate of success in first-line treatment with Sutent, in first-line treatment with IFN-α and in first-line treatment with Bevacizumab + IFN-α [ Time Frame: 9 months ]
  5. Average number of cycles of Sutent, IFN-α and Bevacizumab + IFN in first-line treatment [ Time Frame: 9 months ]

Secondary Outcome Measures :
  1. Percentage of adverse effects with the use of Sunitinib, IFN-α and Bevacizumab + IFN [ Time Frame: 9 months ]
  2. Quality of life in patients using an approved quality questionnaire [ Time Frame: 9 months ]
  3. Costs-benefit of each treatment [ Time Frame: 9 months ]
  4. PFY (progression free years) with each treatment [ Time Frame: 9 months ]
  5. LY (life years) with each treatment [ Time Frame: 9 months ]
  6. QALYs (quality adjusted life years) with each treatment [ Time Frame: 9 months ]
  7. ICER (incremental cost effectiveness ratio) of PFY and LY with each treatment [ Time Frame: 9 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult men and women with mRCC will be evaluated for entering the study. The decision to use Sunitinib, IFN-α or Bevacizumab + IFN must be a joint decision made by the subject and the investigator. The investigator must discuss product information with the subject as per usual practice.

Inclusion Criteria:

  • Evidence of a personally signed (or legally acceptable representative) and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
  • Adult (18 years old or older) men and women with confirmed diagnosis of mRCC treated with Sutent, IFN-α or Bevacizumab + IFN ; on the selected institutions.

Exclusion Criteria:

  • Adult men or women with RCCm treated with any other medication that is not Sutent, IFN-α or Bevacizumab + IFN.
  • Adult men or women with mRCC with palliative care.
  • Adult men or women with RCC without metastasis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01033981

Layout table for location information
Pfizer Investigational Site
Panama City, Panama
Sponsors and Collaborators
Layout table for investigator information
Study Director: Pfizer Call Center Pfizer

Additional Information:
Layout table for additonal information
Responsible Party: Pfizer Identifier: NCT01033981     History of Changes
Other Study ID Numbers: A6181189
First Posted: December 17, 2009    Key Record Dates
Last Update Posted: April 19, 2012
Last Verified: April 2012
Keywords provided by Pfizer:
cost effectiveness
Sunitinib Central America and Caribbean Metastatic Renal Cell Carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action